Peer Exchange
Our Peer Exchange™ program provides a multi-stakeholder perspective on important issues that providers, pharmacists, payers, and patients grapple with as they step into the world of biosimilars.
The experts discuss why the US healthcare system needs biosimilars to succeed.
The panelists discuss the direction of the biosimilars market in the United States.
The panelists discuss whether confirmatory clinical studies will always be needed for biosimilars to be approved in the United States.
The panel discusses how interchangeability may be misunderstood or misrepresented.
The experts discuss the potential for immunogenicity with biosimilar medicines.
Carlos Sattler, MD, discusses how the most sensitive population is identified for phase 3 studies of biosimilars.
The experts consider how comfortable providers are with the extrapolation of indications based on clinical studies in one disease state.
The experts consider clinicians’ awareness of manufacturing changes for reference biologics and their relationship to biosimilarity.
The panelists discuss how much education providers have on the concepts of manufacturing changes and comparability and how those concepts relate to biosimilarity.
Carlos Sattler, MD, analyzes how the FDA has addressed biosimilar education to date.
